Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Mirvetuximab Soravtansine |
Synonyms | |
Therapy Description |
Elahere (mirvetuximab soravtansine) is an antibody-drug conjugate comprised of an antibody directed against FOLR1 linked to the tubulin polymerization-inhibiting drug DM4, leading to cell death in Folr1-expressing tumors (PMID: 26136852, PMID: 25904506). Elahere (mirvetuximab soravtansine) is FDA approved for use in patients with FOLR1-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatments (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mirvetuximab Soravtansine | Elahere | IMGN853|M9346A-sulfo-SPDB-DM4|mirvetuximab soravtansine-gynx | FOLR1-targeted Therapy 17 | Elahere (mirvetuximab soravtansine) is an antibody-drug conjugate comprised of an antibody directed against FOLR1 linked to the tubulin polymerization-inhibiting drug DM4, leading to cell death in Folr1-expressing tumors (PMID: 26136852, PMID: 25904506). Elahere (mirvetuximab soravtansine) is FDA approved for use in patients with FOLR1-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatments (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04296890 | Phase III | Mirvetuximab Soravtansine | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | Completed | USA | ITA | ESP | DEU | BEL | 6 |
NCT04209855 | Phase III | Paclitaxel Pegylated liposomal doxorubicin Mirvetuximab Soravtansine Topotecan | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 14 |
NCT03106077 | Phase II | Mirvetuximab Soravtansine | Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) | Completed | USA | 0 |
NCT05041257 | Phase II | Mirvetuximab Soravtansine | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 2 |
NCT02631876 | Phase II | Paclitaxel + Pegylated liposomal doxorubicin Gemcitabine Topotecan Mirvetuximab Soravtansine | PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer | Completed | USA | ITA | FRA | ESP | CAN | BEL | 7 |
NCT02606305 | Phase I | Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine | Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer | Completed | USA | ESP | CAN | BEL | 0 |
NCT03832361 | Phase II | Mirvetuximab Soravtansine | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer | Recruiting | USA | 0 |
NCT01609556 | Phase I | Mirvetuximab Soravtansine | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors | Completed | USA | CAN | 0 |